^
    Back
    Association details:
    Biomarker:EGFR expression
    Cancer:Glioblastoma
    Drug:losatuxizumab vedotin (ABBV-221) (Microtubule inhibitor, EGFR-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

    Excerpt:
    ABBV-221 has similar activity as depatux-m against an EGFR-amplified GBM patient derived xenograft (PDX) model and is highly effective alone and in combination with standard-of-care temozolomide in an EGFRvIII-positive GBM xenograft model.
    Secondary therapy:
    temozolomide
    DOI:
    10.1158/1535-7163.MCT-17-0710